We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Read MoreHide Full Article
Key Takeaways
MRKR stock rose 114% in three months driven by strong phase I APOLLO data for its lead T-cell therapy MT-601.
MT-601 delivered ~66% response in NHL and 78% in Hodgkin Lymphoma with durable responses.
MRKR advanced MT-601 to dose expansion, secured funding and manufacturing support & expects more data in 1H26.
Marker Therapeutics’ (MRKR - Free Report) shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted investor confidence.
Marker, a Texas-based cancer biotech company, is rapidly advancing its phase I APOLLO study on its lead T-cell therapy, MT-601, in patients with relapsed or refractory B-cell lymphoma.
MRKR’s APOLLO Study Data Positive
In August 2025, data from the study demonstrated encouraging overall responses and a favorable safety profile in heavily pre-treated patients with Non-Hodgkin Lymphoma (NHL). Approximately 66% of patients achieved an objective response and 50% achieved a complete response. Responses were durable, ranging from three to 24 months, with several patients maintaining benefit beyond six months, including responses extending more than one year.
Additionally, MT-601 showed activity in patients with Hodgkin Lymphoma, with a 78% response rate observed.
Based on the positive safety and efficacy results, the company has progressed to the dose expansion phase, evaluating MT-601 at the highest dose in relapsed diffuse large B cell lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T therapy.
Additional clinical data from the study are expected in the first half of 2026, which should be an important catalyst for the stock.
Over the past year, MRKR’s shares have declined 1.8% compared with the industry’s 2.3% fall.
Image Source: Zacks Investment Research
MRKR also plans to initiate clinical studies with MT-601 for pancreatic cancer in the first half of 2026.
The company has also entered into a strategic manufacturing collaboration with Cellipont to scale up production of MT-601, strengthening its manufacturing capabilities.
Progress With MT-401
Alongside MT-601, the company has made progress with its Off-the-Shelf (OTS) platform and treated its first patient in a phase I RAPID study on its OTS candidate, MT-401, in October 2025. The therapy was well-tolerated without any side effects. MT-401 will initially be tested in patients with acute myeloid leukemia or myelodysplastic syndromes, with the potential to be expanded to other indications.
Robust Funding & Extended Cash Runway
The company secured non-dilutive funding from the National Institutes of Health Small Business Innovation Research program, the Cancer Prevention and Research Institute of Texas and the FDA to support the development of MT-601 in metastatic pancreatic cancer and the OTS program.
Marker enhanced its financial position by raising approximately $10 million through its at-the-market facility. This capital raise extends the company’s cash runway well into 2026, providing financial stability to support ongoing clinical development.
Marker currently enjoys solid operational momentum, improved financial flexibility, and has a clearly defined clinical development strategy.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 11.1% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 61.8% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 50% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average earnings surprise being 20.21%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Key Takeaways
Marker Therapeutics’ (MRKR - Free Report) shares have surged approximately 114% over the past three months, driven by strong momentum surrounding its early-stage lead candidate, MT-601, which has boosted investor confidence.
Marker, a Texas-based cancer biotech company, is rapidly advancing its phase I APOLLO study on its lead T-cell therapy, MT-601, in patients with relapsed or refractory B-cell lymphoma.
MRKR’s APOLLO Study Data Positive
In August 2025, data from the study demonstrated encouraging overall responses and a favorable safety profile in heavily pre-treated patients with Non-Hodgkin Lymphoma (NHL). Approximately 66% of patients achieved an objective response and 50% achieved a complete response. Responses were durable, ranging from three to 24 months, with several patients maintaining benefit beyond six months, including responses extending more than one year.
Additionally, MT-601 showed activity in patients with Hodgkin Lymphoma, with a 78% response rate observed.
Based on the positive safety and efficacy results, the company has progressed to the dose expansion phase, evaluating MT-601 at the highest dose in relapsed diffuse large B cell lymphoma patients who have failed or are ineligible for anti-CD19 CAR-T therapy.
Additional clinical data from the study are expected in the first half of 2026, which should be an important catalyst for the stock.
Over the past year, MRKR’s shares have declined 1.8% compared with the industry’s 2.3% fall.
Image Source: Zacks Investment Research
MRKR also plans to initiate clinical studies with MT-601 for pancreatic cancer in the first half of 2026.
The company has also entered into a strategic manufacturing collaboration with Cellipont to scale up production of MT-601, strengthening its manufacturing capabilities.
Progress With MT-401
Alongside MT-601, the company has made progress with its Off-the-Shelf (OTS) platform and treated its first patient in a phase I RAPID study on its OTS candidate, MT-401, in October 2025. The therapy was well-tolerated without any side effects. MT-401 will initially be tested in patients with acute myeloid leukemia or myelodysplastic syndromes, with the potential to be expanded to other indications.
Robust Funding & Extended Cash Runway
The company secured non-dilutive funding from the National Institutes of Health Small Business Innovation Research program, the Cancer Prevention and Research Institute of Texas and the FDA to support the development of MT-601 in metastatic pancreatic cancer and the OTS program.
Marker enhanced its financial position by raising approximately $10 million through its at-the-market facility. This capital raise extends the company’s cash runway well into 2026, providing financial stability to support ongoing clinical development.
Marker currently enjoys solid operational momentum, improved financial flexibility, and has a clearly defined clinical development strategy.
MARKER THERAPEUTICS, INC. Price
MARKER THERAPEUTICS, INC. price | MARKER THERAPEUTICS, INC. Quote
Marker Therapeutics’ Zacks Rank & Stocks to Consider
MRKR currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are MannKind (MNKD - Free Report) , Keros Therapeutics (KROS - Free Report) , and Amicus Therapeutics (FOLD - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for MannKind’s 2026 earnings per share have increased from 7 cents to 9 cents. MNKD shares have declined 11.1% over the past year.
MannKind’s earnings beat estimates in two quarters, missed in one and were in line in the remaining quarter, with the average surprise being 33.33%.
Over the past 60 days, 2026 loss per share estimates for Keros Therapeutics have narrowed from $3.56 to $3.36. KROS shares have surged 61.8% over the past year.
Keros Therapeutics’ earnings beat estimates in three of the trailing four quarters and missed in the remaining quarter, with the average surprise being 9098.63%.
Over the past 60 days, estimates for Amicus Therapeutics’ 2026 earnings per share have declined from 67 cents to 65 cents. FOLD shares have soared 50% over the past year.
Amicus Therapeutics’ earnings beat estimates in one quarter and missed in the remaining three trailing quarters, with the negative average earnings surprise being 20.21%.